Vimarsana
Biggest News Aggregation in the World

Eric Tse News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eric Tse. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eric Tse Today - Breaking & Trending Today

Boehringer Ingelheim Upbeat On China, Forms Cancer Drug Partnership - Vimarsana News

Boehringer Ingelheim Upbeat On China, Forms Cancer Drug Partnership

Country has world's largest number of cancer deaths annually

Source: forbes.com
有片丨香港青年謝承潤在聯合國人權理事會第53屆會議上發言 - Vimarsana News

有片丨香港青年謝承潤在聯合國人權理事會第53屆會議上發言

    Hello, everyone! I am Eric Tse from Hong Kong, China. Today, I am honored to be here and share with you the true situation of Hong Kong's recovery in govern

Source: hkcd.com
Religious smartphone apps promote prayer, meditation -- and falling asleep - Vimarsana News

Religious smartphone apps promote prayer, meditation -- and falling asleep

A pair of Christian-oriented smartphone apps aim to move users closer to God -- and even help believers fall asleep at night.

Photographer Creates Miniature Landmarks On His Dining Table Using Household Items - Vimarsana News

Photographer Creates Miniature Landmarks On His Dining Table Using Household Items

Hong Kong-based photographer Ric Tse creates creative miniature landmarks on his dining table using household items. Ric started creating miniature landmarks on his dining table after the outbreak of coronavirus. In his words “Many photographers and artists have miniature photography, but not

Related Topics:
Eric Tse
Investegate |Samsung Bioepis Announcements | Samsung Bioepis: Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab) - Vimarsana News

Investegate |Samsung Bioepis Announcements | Samsung Bioepis: Health Canada Approves Samsung Bioepis and Biogen's BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab)

Investegate announcements from Samsung Bioepis, Health Canada Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab)